(Q45918039)

English

Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.

scientific article published in December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma. (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

immunosuppression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

author name string

Neel K Gupta

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

Juliet N Barker

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

James W Young

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

publication date

1 December 2009

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

Leukemia & Lymphoma

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

50

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

12

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

2075-2077

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428190903144642

21 January 2018

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428190903144642

21 January 2018

Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428190903144642

21 January 2018

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903144642

21 January 2018

Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience

1 reference

https://api.crossref.org/works/10.3109%2F10428190903144642

21 January 2018

Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428190903144642

21 January 2018

Identifiers

10.3109/10428190903144642

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19637088

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45918039&oldid=1566616585"